RETHINKDEPRESSION
LIVE

Serial Number

98832290

Owner

H. Lundbeck A/S

Attorney

Maren C. Perry

Filing Date

Nov 1, 2024

Add to watchlist:

No watchlists yet
View on USPTO

RETHINKDEPRESSION Trademark

Serial Number: 98832290

RETHINKDEPRESSION is a trademark filed by H. Lundbeck A/S on November 1, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

H. Lundbeck A/S (398 trademarks)

Ottiliavej 9
DK-2500 Copenhagen-Valby , DK

Entity Type: 03

Trademark Details

Filing Date

November 1, 2024

Registration Date

Not Registered

Goods & Services

Education services, namely, arranging and conducting seminars, conferences, symposiums, workshops and courses in the field of medical research and development, science, clinical studies, tests and trials, diagnostic, medicine, pharmaceuticals, disorders, diseases, treatment and prevention; educational and training services in the field of research and development relating to the treatment and prevention of central nervous system diseases and disorders, and pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; providing the aforementioned services electronically, on-line, via cable or Internet or other electronic media; arranging and conducting expert forums, including on-line in the form of seminars, conferences, symposiums, workshops and courses in the field of research and development relating to the treatment and prevention of central nervous system diseases and disorders, and pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; providing on-line training programs in the field of research and development relating to the treatment and prevention of central nervous systems diseases and disorders, and pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; providing on-line publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of research and development relating to the treatment and prevention of central nervous system diseases and disorders and pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; provision of online publications in the nature of books, reports, brochures, booklets, magazines, leaflets, journals, teaching and training materials in the fields of science, clinical trials and tests, diagnostics and medicine; arranging and conducting in-person and online educational expert forums in the fields of science, clinical trials and tests, diagnostics and medicine

Sanitary preparations for medical use; vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of Alzheimer's disease and disorder, stroke, depression, mood disorders, psychosis, anxiety, epilepsy, sclerosis, porphyria, Huntington's disease and disorder, insomnia, Parkinson's disease and disorder, schizophrenia, bipolar disorder and disease, ADHD, oncology, pain, alcoholism and dependency on drugs, alcohol, nicotine and caffeine; diagnostic preparations, substances, reagents and agents for medical purposes

Scientific and technological services, namely, research and design in the field of pharmaceuticals for the treatment and prevention of diseases and disorders of the central nervous system, and pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; industrial analysis and research in the field of research and development relating to the treatment and prevention of diseases and disorders of the central nervous system, and pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; providing online non-downloadable software for accessing data and information in the fields of research and development, science, clinical studies, trials and tests, diagnostics, medicine, pharmaceuticals, disorders, diseases, treatment and prevention; pharmaceutical research and development; scientific and technological services, namely, research and design in the field of disorders, diseases and prevention; scientific and technological services, namely, research and design in the field of central nervous system stimulants, pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases and drugs; medical and scientific research, namely, conducting clinical trials for others; clinical studies tests and trials; pharmaceutical research and development services; medical research; providing information in the field of research and development related to the treatment and prevention of central nervous system stimulants, and pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; provision of medical research information in the fields of research and development, science, clinical studies, trials and tests

Medical services; medical services in the field of central nervous system stimulants, and for the prevention and treatment of psychiatric and neurological disorders and diseases; medical consultancy relating to medical and pharmaceutical preparations; medical, clinical, therapeutic clinical services in the field of central nervous system stimulants, and for the prevention and treatment of psychiatric and neurological disorders and diseases; medical and therapeutic services relating to the treatment and prevention of central nervous system stimulants, and for the prevention and treatment of psychiatric and neurological disorders and diseases; medical, clinical, therapeutic clinical services in the field of central nervous system stimulants, and for the prevention and treatment of psychiatric and neurological disorders and diseases; provision of medical advice and medical information in the field of diagnostics, medicine, drugs, disorders, diseases, treatment and prevention; medical information service, namely, provision of medical information related to the medical dosage, diagnosis, therapeutic topics, medical administration, treatment and prevention of central nervous system disorders and diseases, and for the prevention and treatment of psychiatric and neurological disorders and diseases; provision of online medical data and analytics designed to provide patients and clients with tailored information, on medical dosage, diagnoses, therapeutic topics and medical administration

Filing History

ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Feb 13, 2026 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 6, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 5, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 5, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 5, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 30, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 30, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 30, 2026 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jan 29, 2026 ZZZX
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Apr 10, 2025 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 4, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 4, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 4, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 5, 2024 GNRN
NON-FINAL ACTION E-MAILED
Dec 5, 2024 GNRT
NON-FINAL ACTION WRITTEN
Dec 5, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 2, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 18, 2024 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 18, 2024 NWOS
NEW APPLICATION ENTERED
Nov 1, 2024 NWAP